Serum hepcidin as a biomarker of treatment response in Gaucher disease
Gaucher disease (GD) is a lysosomal disorder associated with hyperferritinemia and altered hepcidin levels. This study evaluated the effect of GD-specific treatment on serum hepcidin and interleukin-6 (IL-6) in seven treatment-naïve Brazilian patients with type 1 GD. Concentrations were measured before and after initiation of treatment. Hepcidin levels significantly decreased and IL-6 showed a downward trend. These results suggest that hepcidin may also exert endocrine effects in GD-related iron metabolism.
Authors
- Ida Vanessa Döederlein Schwartz (ORCID: https://orcid.org/0000-0002-7933-6687)
- Franciele Cabral Pinheiro (ORCID: https://orcid.org/0000-0002-0333-0350)
- Suélen Porto Basgalupp (ORCID: https://orcid.org/0000-0002-3274-8801)
- Marina Siebert (ORCID: https://orcid.org/0000-0003-3366-2177)
- Liane Esteves Daudt (ORCID: https://orcid.org/0000-0001-9495-6932)
- Tiago Koppe
Institutions
- Hospital de Clínicas de Porto Alegre (BR)
Publication Details
- Journal
- Molecular Genetics and Metabolism Reports
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.ymgmr.2025.101255
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00